Dallas, TX (PRWEB) February 25, 2013
The prescription drug resource center DrugRisk.com is alerting patients taking the birth control drugs Yaz or Yasmin of new information to be added to the site showing the latest Yaz settlement figures from Bayer.
“The mission of DrugRisk is to improve patient safety through education. This includes the latest warnings, recalls, studies and litigation news related to popular drugs like Yaz. Informed users can discuss options with their doctor and decide if they need legal advice,” explains DrugRisk representative Ryan Mayer.
The resource center had previously added studies from the British Medical Journal and U.S. FDA which warned birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.*
DrugRisk has also uncovered information from Bayer, the maker of the drugs, indicating more than 12,000 women taking Yaz or Yasmin have filed a lawsuit over side effects like DVT and pulmonary embolism.**
Due to the number of patients filing a Yaz lawsuit, cases were consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).
DrugRisk’s legal news section contains information from Bayer showing the drug maker began settling Yaz cases last spring, and has spent nearly $750 million to settle up to 3,500 Yaz claims.**
Now, the resource center’s Yaz settlement figures will be updated on Thursday, February 28 as Bayer announced they will publish the 2012 full year and 4th quarter financial statements at that time.***
This information will indicate how many additional Yaz lawsuits Bayer has settled, as well as the amount reserved for future victims.
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.
The Drug Risk Resource Center cautions Yaz patients that they should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints"
**Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012